- Advertisement -
Monday, August 15, 2022
Home News Getting into the Driving Seat

Getting into the Driving Seat

If there is one thing about human beings that stands out the most, it’s the way we pursue progression under all circumstances. You see, when you try to get better on a rather consistent basis, you end up giving yourself a pretty solid chance at some notable milestones. Staying with these milestones for a second, we have actually hit upon plenty of them throughout our history, but in all honesty, we are still waiting to see a bigger one than technology. Technology stays a cut above others duo to many reasons. While the creation’s ingenious skill-set is certainly the chief headline here, we can’t be having this conversation without mentioning its reach. Designed to cater different needs, technology had enormous success in impacting our entire spectrum, including the highly-critical area of healthcare. In fact, the famous medtech linkup was so pivotal that it transformed our very outlook towards the sector, and in case the stated change wasn’t enough, we have continued to build further upon this foundation so to enhance our journey even more as we move ahead. Interestingly enough, Regeneron’s latest move does a lot to keep that trend alive.

Regeneron Pharmaceuticals is officially taking full control of its main cancer drug candidate, and to make it happen, it will cough up a whopping $900 million. Meant to particularly treat lung and skin cancer, the drug, Libtayo, has so far been co-marketed by Regeneron and Sanofi. However, with Libtayo poised for regulatory green light in multiple markets, the former would seemingly like to get hold of the entire revenue pie. Talk about the arrangement so far, the partnership agreement, which was struck back in 2015, had seen Sanofi fulfilling commercialization responsibilities outside of US, and that translated to an equal split in global profits. Notably, Sanofi will be moving on from this agreement for much than just the touted $900 million figure. According to certain reports, the company can also expect an 11% royalty on worldwide sales, along with further milestone payments. The first $100 million of these milestone payments will depend largely on Libtayo bagging regulatory approval in US or Europe for a new application that will link-up the drug with chemotherapy for the purpose of treating patients suffering from non-small cell lung cancer. The remaining milestone payments revolve at length around the drug’s sales.

“This strategic acquisition is a major step towards Regeneron’s goal of becoming a global oncology leader, centered on Libtayo as an important choice in settings where PD-1 inhibitors can be used as monotherapy and, excitingly, in potential new combinations with our differentiated and diverse pipeline of oncology assets,” said Leonard Schleifer, CEO of Regeneron Pharmaceuticals.

Must Read

Data Sciences in the Medical Industry: How powerful is it?

When novel compounds were researched about, to meet the needs of patients who were in critical conditions, medical science had huge growth....

A Smarter Way Out of a Huge Healthcare Challenge

Yes, there are many things that come together to make human beings special, but if we are being honest, nothing does the job quite...

How Patient Complaints Can Help Your Medical Practice Grow

Let’s face it, no one wants to hear negative criticism. We would all like to think we are doing a great job at any...

Betting Big on a Rejuvenated Pharmaceutical Landscape

A human skill-set is literally made up from various valuable elements, and yet nothing there can claim to be more valuable than our tendency...

Related News

Connecting the Healthcare Dots

A human arsenal is known to contain some hugely valuable components, but if we care to be honest for a second, none of those...

Reinventing those Vaccination Drives

There are many different ways through which we can define human beings, but if we are being honest, none do the job quite like...

Finding the Healthcare Equilibrium

One of the many things that make human beings so special is our very tendency to grow on a consistent basis. In fact, if...

Constructing a Smarter Healthcare Ground

If you ponder on the question of why human beings are so unique, you’ll likely come across various different factors, but the one that...

Conceiving Smarter Healthcare Avenues

One of the best things about a human life is how you can always make it better it in one way or the other....